TNF and COVID-19: In the international registry database of COVID-19 in patients with IBD (SECURE-IBD), corticosteroids but not antitumor necrosis factor (anti-TNF) were associated with adverse outcomes of the COVID-19 infection (odds ratio (OR): 6.9; 95% CI: 2.3–20.5) [15].